Sergolexole: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 32: | Line 32: | ||
[[Category:Restless legs syndrome]] | [[Category:Restless legs syndrome]] | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
<gallery> | |||
File:Sergolexole structure.png|Sergolexole | |||
</gallery> | |||
Latest revision as of 01:30, 20 February 2025
Sergolexole is a pharmaceutical drug that belongs to the class of serotonin receptor agonists. It is primarily used in the treatment of Parkinson's disease and restless legs syndrome. Sergolexole works by stimulating the serotonin receptors in the brain, which helps to control and regulate mood, appetite, and sleep.
History[edit]
Sergolexole was first synthesized in the late 20th century as part of a broader effort to develop new treatments for neurological disorders. The drug was initially tested in animal models before being approved for human use.
Pharmacology[edit]
Sergolexole is a potent and selective agonist at the 5-HT1A and 5-HT1B serotonin receptors. It is believed to work by increasing the activity of these receptors in the brain, which can help to alleviate the symptoms of Parkinson's disease and restless legs syndrome.
Clinical Use[edit]
Sergolexole is primarily used in the treatment of Parkinson's disease and restless legs syndrome. It is typically administered orally, and the dosage is adjusted based on the patient's response to treatment.
Side Effects[edit]
Like all drugs, Sergolexole can cause side effects. The most common side effects include nausea, dizziness, and sleepiness. In rare cases, Sergolexole can cause more serious side effects such as hallucinations and compulsive behaviors.
See Also[edit]
References[edit]
<references group="" responsive="1"></references>
-
Sergolexole
